Physician profile
Ronald C Evans
NPI 1891701744
$1,838.65
in general payments reported to CMS, 2019-2025
19 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $38.84 · 2021: $228 · 2022: $304 · 2023: $367 · 2024: $312 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $664.85 | 2022-2025 | |
| Alcon Vision LLC | $173.97 | 2021-2025 | Argos, Rocklatan, Clareon |
| Aerie Pharmaceuticals, INC. | $131.44 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $99.53 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $92.87 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $92.01 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $85.49 | 2019-2020 | |
| Allergan, INC. | $77.27 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $66.97 | 2023 | Acthar |
| Dompe US, INC. | $60.71 | 2021-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $50.07 | 2019 | |
| Rxsight INC | $40.01 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $37.06 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $36.61 | 2019 | |
| Ivantis, INC | $35.92 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $35.72 | 2021-2025 | |
| Johnson & Johnson Vision Care, INC. | $21.59 | 2023 | Acuvue |
| Apellis Pharmaceuticals, INC. | $19.65 | 2025 | Syfovre |
| Bausch & Lomb Americas INC. | $16.91 | 2023 | Vyzulta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.